T-cell therapy is the most efficacious approach for many patients with relapsed/refractory multiple myeloma, but it currently comes with 2 periods ...
Limited proactive offering of video visits by oncology teams, especially for nonusers, reduced exposure and normalized ...
Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes ...
In this episode of Community Corner, Christopher H. Lieu, MD, professor of medicine at the University of Colorado Cancer ...
MSK researchers found that BRCA2 mutations lower the barrier for RB1 loss, causing CDK4/6 inhibitor resistance.
Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer ...
FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...
Day-45 MRD clearance favored cema-cel over observation by an absolute 41.6% in the first 24 evaluable patients, satisfying ...
Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists. Lung cancer treatment has undergone a remarkable transformation ...
Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with ...
New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter ...
Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results